Edwards Lifesciences to Acquire Innovalve

July 15, 2024—Edwards Lifesciences announced it has exercised its option to acquire Innovalve Bio Medical Ltd., an early-stage transcatheter mitral valve replacement (TMVR) company.

Edwards stated that since its initial investment in the company in 2017, Innovalve has demonstrated progress in its program with promising early clinical experience.

Innovalve will join Edwards’ transcatheter mitral and tricuspid therapies product group, led by corporate vice president, Daveen Chopra. The acquisition is expected to close by the end of 2024, advised the company.

“Building on our learnings of the complexity of mitral disease, we know there is a need for a differentiated range of therapies for these patients,” commented Chopra in the company’s press release. “Edwards’ Sapien M3 remains on track to become the first approved transfemoral TMVR system in Europe by the end of 2025. We believe the Innovalve technologies, paired with Edwards’ deep mitral expertise, will enable a TMVR platform that will expand the treatable population.”